Expert Recommendations in Relapsed/Refractory Multiple Myeloma

In this on demand webcast, expert faculty discuss best practices in treating patients
with relapsed/refractory multiple myeloma. 

MYSummit Myeloma Conference - Cancelled

Due to the impact of COVID-19, the MYSummit Conference
has been cancelled

Myeloma News

Keep up to date on the latest multiple myeloma news and information.

Featured Content

Myeloma News

Recent Publications

Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study

Lancet. 2021 Jul 24;398(10297):314-324. doi: 10.1016/S0140-6736(21)00933-8. Epub 2021 Jun 24.ABSTRACTBACKGROUND: CARTITUDE-1 aimed to assess the safety and clinical activity of ciltacabtagene autoleucel (cilta-cel), a chimeric antigen receptor T-cell therapy with two...

Myeloma Bone Disease: A Comprehensive Review

Int J Mol Sci. 2021 Jun 8;22(12):6208. doi: 10.3390/ijms22126208.ABSTRACTMultiple myeloma (MM) is a neoplastic clonal proliferation of plasma cells in the bone marrow microenvironment, characterized by overproduction of heavy- and light-chain monoclonal proteins...

Twitter Discussions